×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
APTO – aptose biosciences, inc. - common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
APTO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/31
02:44 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/23
02:07 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/19
05:28 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Canadian Business Journal (Canada)]
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Canadian Business Journal (Canada)]
12/19
04:17 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Yahoo! Finance]
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel [Yahoo! Finance]
12/19
04:05 pm
apto
Aptose Announces Positive Decision by Nasdaq Hearings Panel
High
Report
Aptose Announces Positive Decision by Nasdaq Hearings Panel
12/15
02:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
12/12
10:15 am
apto
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
Low
Report
Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib’s Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax
12/10
08:01 am
apto
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/30
06:01 am
apto
Form DEF 14A Aptose Biosciences Inc. For: Jan 27
Low
Report
Form DEF 14A Aptose Biosciences Inc. For: Jan 27
12/30
06:01 am
apto
Form DEFA14A Aptose Biosciences Inc.
Low
Report
Form DEFA14A Aptose Biosciences Inc.
12/19
04:10 pm
apto
Form 8-K Aptose Biosciences Inc. For: Dec 19
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Dec 19
12/13
05:04 pm
apto
Form PRE 14A Aptose Biosciences Inc. For: Jan 27
Low
Report
Form PRE 14A Aptose Biosciences Inc. For: Jan 27
12/12
10:30 am
apto
Form 8-K Aptose Biosciences Inc. For: Dec 12
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Dec 12
12/9
12:06 pm
apto
Form 8-K Aptose Biosciences Inc. For: Dec 09
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Dec 09
12/3
07:45 am
apto
Form 8-K Aptose Biosciences Inc. For: Dec 03
Medium
Report
Form 8-K Aptose Biosciences Inc. For: Dec 03
11/26
06:57 pm
apto
Form 4 Aptose Biosciences Inc. For: Nov 25 Filed by: Rice William G.
Low
Report
Form 4 Aptose Biosciences Inc. For: Nov 25 Filed by: Rice William G.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/7
Aptose Presents Highlights From Corporate Event At ASH
35.1%
3/12 Form 4 Aptose Biosciences Inc. For: Mar 10 Filed by: Chow Gregory K. 20.7%
1/9 Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock. 10.0%
5/30 Aptose Announces Pricing of Public Offering of Common Shares 9.9%
12/18 Form 424B5 Aptose Biosciences Inc. 9.3%
5/29 Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at Roth Capital. 8.7%
10/22 Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019 8.5%
4/14 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.50 price target on the stock. 8.0%
3/16 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock. 7.6%
1/29 Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference 7.2%
3/12 Form 4 Aptose Biosciences Inc. For: Mar 10 Filed by: Chow Gregory K. 20.7%
1/9 Aptose Biosciences Inc. (NASDAQ: APTO) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $10.00 price target on the stock. 10.0%
5/30 Aptose Announces Pricing of Public Offering of Common Shares 9.9%
12/18 Form 424B5 Aptose Biosciences Inc. 9.3%
5/29 Aptose Biosciences Inc. (NASDAQ: APTO) had its "buy" rating re-affirmed by analysts at Roth Capital. 8.7%
10/22 Aptose To Release Third Quarter Ended September 30, 2019 Financial Results and Hold Conference Call on November 5, 2019 8.5%
4/14 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $7.50 price target on the stock. 8.0%
3/16 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.00 price target on the stock. 7.6%
1/29 Aptose Biosciences to Host Key Opinion Leader Event Present at BIO CEO & Investor Conference 7.2%
TOP News Decliners
3/10
Form 10-K Aptose Biosciences Inc. For: Dec 31
-21.6%
3/12 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -18.3%
4/27 Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020 -12.6%
12/17 Aptose up 3% after pricing stock offering [Seeking Alpha] -11.7%
8/6 Form 8-K Aptose Biosciences Inc. For: Aug 06 -9.7%
4/29 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.3%
3/13 Form 4 Aptose Biosciences Inc. For: Mar 11 Filed by: PLATZER ERICH -8.8%
5/29 Aptose Announces Proposed Public Offering of Common Shares -7.4%
12/24 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.3%
9/16 Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies -7.2%
3/12 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -18.3%
4/27 Aptose Presents Preliminary Clinical Data on CG-806 at AACR Virtual Annual Meeting 2020 -12.6%
12/17 Aptose up 3% after pricing stock offering [Seeking Alpha] -11.7%
8/6 Form 8-K Aptose Biosciences Inc. For: Aug 06 -9.7%
4/29 Aptose Biosciences Inc. (NASDAQ: APTO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.3%
3/13 Form 4 Aptose Biosciences Inc. For: Mar 11 Filed by: PLATZER ERICH -8.8%
5/29 Aptose Announces Proposed Public Offering of Common Shares -7.4%
12/24 Aptose Biosciences Inc. (NASDAQ: APTO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -7.3%
9/16 Aptose to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies -7.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: